Argus Pharmaceuticals Inc. of The Woodlands, Texas, hascreated a seven-member scientific advisory board comprisedof experts in immunology, oncology, infectious disease andbiochemistry.

The board includes Dr. Gabriel Lopez-Berestein, an Argusfounder and professor of medicine and chief of theimmunobiology and drug carriers section at the University ofTexas M.D. Anderson Cancer Center; Dr. Gianni Bonadonna,professor of clinical hematology at the University of Milan; Dr.Edwin C. Cadman, ensign professor and chairman of thedepartment of internal medicine at Yale University School ofMedicine; Dr. Luis T. Campos, clinical assistant professor ofthe department of internal medicine at the University of TexasMedical School in Houston; Michael Anthony Chirigos, Ph.D.,deputy of science at the U.S. Army Medical Research Instituteof Infectious Diseases prior to his retirement earlier thisyear; David W. Deamer, Ph.D., professor of cell biology at theUniversity of California, Davis; Dr. Albert Deisseroth, Andersonprofessor of cancer treatment and research and chairman ofthe department of hematology at M.D. Anderson Cancer Centerand adjunct professor of medicine at Baylor College ofMedicine; Dr. Jack S. Remington, chairman of the department ofimmunology and infectious diseases at the Research Instituteof the Palo Alto Medical Foundation and professor of thedepartment of medicine at the division of infectious diseasesat Stanford University.

Argus develops new drugs and drug carrier systems for thetreatment of cancer and serious infections.

Dr. Irvin D. Smith has been appointed managing director ofBioferon Biochemische Substanzen GmbH, a company thatBiogen Inc. owns jointly with Dr. Rentschler ArzneimittelGmbH & Co. Bioferon of Lauphiem, Germany, currently producesgamma and beta interferon for commercial sale. Smith waspreviously president and chief executive officer at AppliedBiosystems Inc. Biogen (NASDAQ:BGEN) of Cambridge, Mass., isfocused on products used to treat cardiovascular andinflammatory disease, AIDS, and certain cancers.

Synthecell Corp. has added three members to its board: RobertK. Dressing, president of the Cystic Fibrosis Foundation;Sanford G. Henry, former managing director of the LazardMedical Fund; and Terry L. Lierman, president of CapitolAssociates. Rockville, Md.-based Synthecell specializes inantisense technology and manufactures custom synthetic DNAand peptides.

(c) 1997 American Health Consultants. All rights reserved.